NAS:AXSM (USA)
Business Description
Axsome Therapeutics Inc
NAICS : 325412
SIC : 2834
22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007
Compare
Compare
Traded in other countries / regions
19X.Germany
•
AZSM.Mexico
•
0HKF.UK
•
AXSM.USA
Description
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.78 | |||||
| Equity-to-Asset | 0.08 | |||||
| Debt-to-Equity | 6.2 | |||||
| Debt-to-EBITDA | -0.67 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0.8 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -43.6 | |||||
| 3-Year EPS without NRI Growth Rate | -44.5 | |||||
| 3-Year FCF Growth Rate | -37.1 | |||||
| 3-Year Book Growth Rate | 137.1 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.21 | |||||
| 9-Day RSI | 64.25 | |||||
| 14-Day RSI | 62.34 | |||||
| 6-1 Month Momentum % | 31.1 | |||||
| 12-1 Month Momentum % | 72.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.44 | |||||
| Quick Ratio | 2.2 | |||||
| Cash Ratio | 1.72 | |||||
| Days Inventory | 3833.43 | |||||
| Days Sales Outstanding | 669.08 | |||||
| Days Payable | 5210.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.9 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.85 | |||||
| Operating Margin % | -1636.56 | |||||
| Net Margin % | -1699.89 | |||||
| ROE % | -469.46 | |||||
| ROA % | -121.54 | |||||
| ROIC % | -662.1 | |||||
| ROC (Joel Greenblatt) % | -11578.84 | |||||
| ROCE % | -149.77 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 204.73 | |||||
| PB Ratio | 121.44 | |||||
| EV-to-EBIT | -13.14 | |||||
| EV-to-EBITDA | -13.35 | |||||
| EV-to-Revenue | 213.79 | |||||
| EV-to-Forward-Revenue | 29.49 | |||||
| EV-to-FCF | -15.39 | |||||
| Earnings Yield (Greenblatt) % | -7.61 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:AXSM
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8.82 | ||
| EPS (TTM) ($) | -3.92 | ||
| Beta | 1.52 | ||
| Volatility % | 105.72 | ||
| 14-Day RSI | 62.34 | ||
| 14-Day ATR ($) | 3.317766 | ||
| 20-Day SMA ($) | 41.33 | ||
| 12-1 Month Momentum % | 72.89 | ||
| 52-Week Range ($) | 19.38 - 48.82 | ||
| Shares Outstanding (Mil) | 40.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Axsome Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||